biologic

Humulin R U-100

insulin human

Loss of exclusivityMay 2030projected — 12-year biologic exclusivity estimate
CompanyEli Lilly and Company

Drug detail

Brand nameHumulin R U-100
Active ingredientinsulin human
Strength300UNITS/3ML (100UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2018
Marketing statusOTC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humulin R U-100 patent cliff — loss of exclusivity May 2030 | CliffBio